Skip to contentSkip to filters

We use cookies for analytics.

Alzheimer's

10 results

Upcoming first, then newest

This free hybrid conference connects emerging Alzheimer’s and dementia researchers and clinicians across molecular biology, genetics, drug development and related neuroscience. A live virtual core programme links local hubs in Bangkok, Cairo, Ljubljana and Nicosia, with mentoring, networking and career-development opportunities. All participants complete the global registration; those attending physically also complete a separate registration for their chosen hub.

Feb 15–18, 2027

Conference · Neuroscience

Supports translational studies of potential Alzheimer’s and related-dementia therapies, including early human safety, target engagement and proof of mechanism. Awards provide up to USD 1 million over two to three years; selected Phase 3 or biomarker-validation proposals can also qualify. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

Closed

Grant · Clinical Neurology

Compensation by dynamics: Functional connectivity rescued from structural damage by modulating dynamical regime

Samy Castro Novoa, Sophie Benitez-Stulz, Gregory Dumont et al. · FENS Forum 2024

Aging and neurodegenerative diseases, such as Alzheimer's (AD) or Amyotrophic Lateral Sclerosis (ALS), led to widespread degeneration of long-range connections in cortical structural connectivity (SC). These damages manifest as losses in connections or demyelination of axons. When the SC of the brain is damaged, the functional connectivity (FC, i.e. the dynamic interactions and information exchange between distinct brain regions) is locally and globally perturbed. Despite the close correlation between SC and FC, they are not identical; FC exhibits greater flexibility and can reorganize in resp

ePoster · Neuroscience

Coregraph is a tool under development that allows us to collect high-density data patterns during the administration of classic neuropsychological tests such as the Trail Making Test and Clock Drawing Test. These tests are widely used to evaluate cognitive function and screen for neurodegenerative disorders, but traditional methods of data collection only yield sparse information, such as test completion time or error types. By contrast, the high-density data collected with Coregraph may contribute to a better understanding of the cognitive processes involved in executing these tests. In addit

Wed, Feb 8, 2023 · 14:00 UTC

Seminar · Cognition

Human stem cell models of Alzheimer’s disease and frontotemporal dementia

Selina Wray · UCL Queen Square institute of Neurology

…our work using iPSC to modal familial Alzheimer's Disease (fAD) and Frontotemporal Dementia (FTD). We have investigated the mutation-specific effects of APP and PSEN1 mutations on Abeta generation in neurons generated from individuals with fAD, revealing distinct mechanisms that may contribute to clinical heterogeneity in disease. I will also discuss our work to und

Mon, Apr 11, 2022 · 11:00 UTC

Seminar · Cell Biology

…with the fact that the prevalence of Alzheimer's Disease increases exponentially with age makes for a worrying combination. Mild cognitive impairment (MCI) is an intermediate stage of cognitive decline between being cognitively normal and having full-blown Dementia, with every third person with MCI progressing to dementia of the Alzheimer's Type (DAT). While there is no known way to reverse symptoms once they begin, early prediction of d

Fri, Mar 25, 2022 · 09:00 UTC

Seminar · Clinical Neurology

Biopsychosocial pathways in dementia inequalities

Laura Zahodne · Psychology, University of Michigan

In the United States, racial/ethnic inequalities in Alzheimer's disease and related dementias persist even after controlling for socioeconomic factors and physical health. These persistent and unexplained disparities suggest: (1) there are unrecognized dementia risk factors that are socially patterned and/or (2) known dementia risk factors exhibit differential impact across social groups. Pursuing these research directions with data from multiple longitudinal studies of brain and cognitive aging has revealed several challenges to the study of late-life health inequalities, highlighted evidence

Mon, Mar 21, 2022 · 07:00 UTC

Seminar · Epidemiology

Toxic effect of pathogenic tau on the nucleus

Bess Frost · University of Texas Health San Antonio

The nuclear envelope is a lipid bilayer that encases the genome and provides a physical boundary between the cytoplasm and the nucleoplasm. While the nucleus is typically depicted as a sphere encircled by a smooth surface of nuclear envelope, the smooth exterior can be interrupted by tubular invaginations of the nuclear envelope into the deep nuclear interior. Such structures are termed the "nucleoplasmic reticulum." Increased frequency of nuclear envelope invagination occurs in disease states including various cancers, viral infections, and laminopathies, a group of heterogeneous disorders th

Wed, May 26, 2021 · 05:00 UTC

Seminar · Cell Biology

Blood phosphorylated tau as biomarkers for Alzheimer’s disease

Thomas K. Karikari · University of Gothenburg

Alzheimer's disease (AD) is the most common cause of dementia, and its health and socioeconomic burdens are of major concern. Presently, a definite diagnosis of AD is established by examining brain tissue after death. These examinations focus on two major pathological hallmarks of AD in the brain: (i) amyloid plaques consisting of aggregated amyloid beta (Aβ) peptides and (ii) neurofibrillary tangles made of abnormally phosphorylated tau protein. In living individuals, AD diagnosis relies on two main approaches: (i) brain imaging of tau tangles and Aβ plaques using a technique called positron

Thu, Dec 10, 2020 · 15:00 UTC

Seminar · Clinical Neurology